{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,10]],"date-time":"2026-01-10T18:51:53Z","timestamp":1768071113511,"version":"3.49.0"},"reference-count":31,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2016,8,20]],"date-time":"2016-08-20T00:00:00Z","timestamp":1471651200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"name":"Minophagen Pharmaceutical"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["The Journal of Dermatology"],"published-print":{"date-parts":[[2017,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Safety, tolerability, pharmacokinetics and efficacy of bexarotene, a novel retinoid X receptor (<jats:styled-content style=\"fixed-case\">RXR<\/jats:styled-content>)\u2010selective retinoid, were evaluated in Japanese patients with stage <jats:styled-content style=\"fixed-case\">IIB<\/jats:styled-content>\u2013<jats:styled-content style=\"fixed-case\">IVB<\/jats:styled-content> and relapsed\/refractory stage <jats:styled-content style=\"fixed-case\">IB<\/jats:styled-content>\u2013<jats:styled-content style=\"fixed-case\">IIA<\/jats:styled-content> cutaneous T\u2010cell lymphomas (<jats:styled-content style=\"fixed-case\">CTCL<\/jats:styled-content>). This study was conducted as a multicenter, open\u2010label, historically controlled, single\u2010arm phase <jats:styled-content style=\"fixed-case\">I\/II<\/jats:styled-content> study. Bexarotene was p.o. administrated once daily at a dose of 300 mg\/m<jats:sup>2<\/jats:sup> for 24 weeks in 13 patients, following an evaluation of safety and tolerability for 4 weeks at a dose of 150 mg\/m<jats:sup>2<\/jats:sup> in three patients. Eight of 13 patients (61.5%) with an initial dose of 300 mg\/m<jats:sup>2<\/jats:sup> met the response criteria using the modified severity\u2010weighted assessment tool (<jats:styled-content style=\"fixed-case\">mSWAT<\/jats:styled-content>) at 24 weeks or discontinuation. Dose\u2010limiting toxic effects (<jats:styled-content style=\"fixed-case\">DLT<\/jats:styled-content>) were present in four of 13 patients (31%) at a dose of 300 mg\/m<jats:sup>2<\/jats:sup>: two neutropenia, one abnormal hepatic function and one hypertriglyceridemia. No <jats:styled-content style=\"fixed-case\">DLT<\/jats:styled-content> was observed in patients received 150 mg\/m<jats:sup>2<\/jats:sup> bexarotene. In the 13 patients at 300 mg\/m<jats:sup>2<\/jats:sup>, common drug\u2010related adverse events (<jats:styled-content style=\"fixed-case\">AE<\/jats:styled-content>) included hypothyroidism (92%), hypercholesterolemia (77%), leukopenia or neutropenia (39%), nasopharyngitis or anemia (31%). The treatment\u2010related grade 3 <jats:styled-content style=\"fixed-case\">AE<\/jats:styled-content> included hypertriglyceridemia (4\/16 patients, 25%), increased alanine aminotransferase, increased aspartate aminotransferase, dyslipidaemia, leukopenia and neutropenia (1\/16 patients, 6%), and one of 16 patients experienced grade 4 hypertriglyceridemia. No patients discontinued bexarotene due to the <jats:styled-content style=\"fixed-case\">AE<\/jats:styled-content> during the study, but dose reduction or suspension was required. Bexarotene was shown to be well tolerated at 300 mg\/m<jats:sup>2<\/jats:sup> once daily and effective in Japanese patients with <jats:styled-content style=\"fixed-case\">CTCL<\/jats:styled-content>.<\/jats:p>","DOI":"10.1111\/1346-8138.13542","type":"journal-article","created":{"date-parts":[[2016,8,20]],"date-time":"2016-08-20T11:22:45Z","timestamp":1471692165000},"page":"135-142","source":"Crossref","is-referenced-by-count":36,"title":["Phase I\/II study of the oral retinoid X receptor agonist bexarotene in Japanese patients with cutaneous T\u2010cell lymphomas"],"prefix":"10.1111","volume":"44","author":[{"given":"Toshihisa","family":"Hamada","sequence":"first","affiliation":[{"name":"Department of Dermatology Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences Okayama Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Makoto","family":"Sugaya","sequence":"additional","affiliation":[{"name":"Department of Dermatology Faculty of Medicine University of Tokyo Tokyo Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshiki","family":"Tokura","sequence":"additional","affiliation":[{"name":"Department of Dermatology Hamamatsu University School of Medicine Shizuoka Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mikio","family":"Ohtsuka","sequence":"additional","affiliation":[{"name":"Department of Dermatology Fukushima Medical University Fukushima Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryoji","family":"Tsuboi","sequence":"additional","affiliation":[{"name":"Department of Dermatology Tokyo Medical University Tokyo Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tetsuo","family":"Nagatani","sequence":"additional","affiliation":[{"name":"Department of Dermatology Tokyo Medical University Hachioji Medical Center Tokyo Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mamori","family":"Tani","sequence":"additional","affiliation":[{"name":"Department of Dermatology Osaka University Graduate School of Medicine Osaka Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mitsuru","family":"Setoyama","sequence":"additional","affiliation":[{"name":"Department of Dermatology Faculty of Medicine University of Miyazaki Miyazaki Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shigeto","family":"Matsushita","sequence":"additional","affiliation":[{"name":"Department of Dermatology Kagoshima University Graduate School of Medical and Dental Sciences Kagoshima Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9375-0713","authenticated-orcid":false,"given":"Kazuhiro","family":"Kawai","sequence":"additional","affiliation":[{"name":"Department of Dermatology Kagoshima University Graduate School of Medical and Dental Sciences Kagoshima Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kentaro","family":"Yonekura","sequence":"additional","affiliation":[{"name":"Department of Dermatology Imamura Bun\u2010in Hospital Kagoshima Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tsuyoshi","family":"Yoshida","sequence":"additional","affiliation":[{"name":"Minophagen Pharmaceutical Tokyo Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshiaki","family":"Saida","sequence":"additional","affiliation":[{"name":"Department of Dermatology Shinshu University Nagano Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keiji","family":"Iwatsuki","sequence":"additional","affiliation":[{"name":"Department of Dermatology Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences Okayama Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2016,8,20]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-10-184168"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.143.7.854"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.12299"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.12346"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1529-8019.2006.00083.x"},{"key":"e_1_2_7_7_1","first-page":"106","article-title":"All\u2010trans retinoic acid in hematological malignancies, an update. GER (Gruppo Ematologico Retinoidi)","volume":"82","author":"Sacchi S","year":"1997","journal-title":"Haematologica"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.1987.01660260071016"},{"key":"e_1_2_7_9_1","doi-asserted-by":"crossref","first-page":"232","DOI":"10.2340\/0001555567232236","article-title":"Oral retinoids in mycosis fungoides and S\u00e9zary syndrome: a comparison of isotretinoin and etretinate. A study from the Scandinavian Mycosis Fungoides Group","volume":"67","author":"Molin L","year":"1987","journal-title":"Acta Derm Venereol"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.1983.tb03991.x"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(83)92136-0"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1038\/330444a0"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1038\/330624a0"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1038\/332850a0"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.86.14.5310"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1101\/gad.6.3.329"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1038\/358771a0"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.90.6.2160"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1124\/pr.58.4.5"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/0092-8674(92)90478-U"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1038\/355441a0"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1002\/j.1460-2075.1992.tb05186.x"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1038\/358587a0"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1038\/383450a0"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1128\/MCB.15.7.3540"},{"key":"e_1_2_7_26_1","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.1182\/blood.V87.5.1977.1977","article-title":"Effects of novel retinoid X receptor\u2010selective ligands on myeloid leukemia differentiation and proliferation in vitro","volume":"87","author":"Kizaki M","year":"1996","journal-title":"Blood"},{"key":"e_1_2_7_27_1","first-page":"5919","article-title":"Abrogation of transforming growth factor\u2010alpha\/epidermal growth factor receptor autocrine signaling by an RXR\u2010selective retinoid (LGD1069, Targretin) in head and neck cancer cell lines","volume":"61","author":"Song JI","year":"2001","journal-title":"Cancer Res"},{"key":"e_1_2_7_28_1","first-page":"1234","article-title":"Induction of apoptosis by bexarotene in cutaneous T\u2010cell lymphoma cells: relevance to mechanism of therapeutic action","volume":"8","author":"Zhang C","year":"2002","journal-title":"Clin Cancer Res"},{"key":"e_1_2_7_29_1","first-page":"581","article-title":"Phase 2 and 3 clinical trial of oral bexarotene (Targretin capsules) for the treatment of refractory or persistent early\u2010stage cutaneous T\u2010cell lymphoma","volume":"137","author":"Duvic M","year":"2001","journal-title":"Arch Dermatol"},{"key":"e_1_2_7_30_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.9.2456"},{"key":"e_1_2_7_31_1","first-page":"296","article-title":"WHO classification of tumours of haematopoietic and lymphoid tissues","author":"Ralfkiaer E","journal-title":"Lyon: IARC"},{"key":"e_1_2_7_32_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.10.2434"}],"container-title":["The Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2F1346-8138.13542","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2F1346-8138.13542","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/1346-8138.13542","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,24]],"date-time":"2023-09-24T15:07:25Z","timestamp":1695568045000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/1346-8138.13542"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,8,20]]},"references-count":31,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017,2]]}},"alternative-id":["10.1111\/1346-8138.13542"],"URL":"https:\/\/doi.org\/10.1111\/1346-8138.13542","archive":["Portico"],"relation":{},"ISSN":["0385-2407","1346-8138"],"issn-type":[{"value":"0385-2407","type":"print"},{"value":"1346-8138","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,8,20]]}}}